Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey

Leukemia
F LauriaS Tura

Abstract

Between January 1991 and January 1994, 40 patients with hairy-cell leukemia (HCL), 30 males and 10 females, with a median age of 54 years, were treated with a single course of 2-chlorodeoxyadenosine (2-CdA) at a dose of 0.1 mg/kg/day continuous infusion for 7 days. Thirteen patients were untreated and 27 had previously received alpha-interferon. Thirty out of 40 patients (75%) achieved complete remission (CR) and 10 (25%) partial remission (PR). The median follow-up duration for patients in CR has been 48 months (range 30-66). Five of the complete responders (17%) relapsed at 12, 24, 26, 30 and 36 months after treatment as documented by the increase of hairy cells (Hc) in the bone marrow and two of them, who were retreated with 2-CdA after showing an initial impairment of peripheral blood values, obtained a second CR. The remaining three relapsed patients were never retreated and still show normal peripheral counts after 30, 38 and 40 months. Twelve of the continuous complete responder patients are still in CR after more than 5 years. In contrast, 8 out of 10 partial responders progressed after 8-36 months and all of them were retreated with 2-CdA at a dose of 0.15 mg/kg/day for 5 days i.v. Four of them (50%) achieved a CR, thr...Continue Reading

Citations

May 6, 2006·Cancer Immunology, Immunotherapy : CII·Jing-Sheng Hao, Bao-En Shan
Oct 7, 2005·International Journal of Hematology·Takashi MachiiUNKNOWN Cladribine Study Group
Apr 21, 2011·Leukemia & Lymphoma·Francesco LauriaFrancesco Forconi
May 10, 2002·Leukemia & Lymphoma·David W GoldeMark L Heaney
Oct 21, 2009·Leukemia & Lymphoma·Martin S Tallman, Aaron Polliack
Jun 24, 2004·Expert Opinion on Pharmacotherapy·Francesco Lauria, Francesco Forconi
Dec 17, 2009·Expert Opinion on Drug Safety·Constantin A DasanuDoru T Alexandrescu
Jul 22, 2006·European Journal of Haematology·Giuseppe MarottaUNKNOWN Italian Cooperative group for HCL (ICGHCL)
Nov 25, 2011·British Journal of Haematology·Gail JonesUNKNOWN British Committee for Standards in Haematology
Jun 21, 2005·Blood Reviews·Farhad Ravandi, Susan O'Brien
Aug 31, 2004·Journal of Chemotherapy·G CervettiM Petrini
Mar 20, 2009·La Presse médicale·Noël Milpied
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P L ZinzaniS Tura
Nov 20, 1998·European Journal of Haematology·E V Ikpeazu, M K Kaplon
Aug 7, 2020·Biomolecules·Robert J Kreitman, Ira Pastan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.